European Pharmaceutical Review

SEPTEMBER 21, 2022

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1 Safety update.

Generic Medicine 98

Generic Medicine Vaccines 98

European Pharmaceutical Review

NOVEMBER 14, 2022

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. Read highlights from the CHMP’s September 2022 meeting. COVID-19 update.

Vaccines 98

Vaccines Generic Medicine 98

European Pharmaceutical Review

DECEMBER 19, 2022

A generic medicine, Diethyl fumarate Accord (dimethyl fumarate), received a positive opinion for the treatment of multiple sclerosis (MS), a chronic disease affecting the central nervous system. The committee recommended to extend the use of original Spikevax vaccine and Spikevax bivalent Original/Omicron BA.1 COVID-19 update.

Generic Medicine 104

Generic Medicine Vaccines Chemotherapy 104

pharmaphorum

MARCH 29, 2022

With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.

Vaccines 95

Vaccines Generic Medicine 95

STAT

OCTOBER 10, 2023

The state’s biotech scene   exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. But the   drumbeat of layoffs in 2022   has only grown louder this year.

Vaccines 136

Vaccines Generic Medicine Packaging 136

European Pharmaceutical Review

APRIL 3, 2023

It is the eighth vaccine recommended in the European Union (EU) for COVID-19. CHMP’s January 2023 meeting highlights… Read the EMA’s human medicines highlights 2022 report. The committee adopted a positive opinion for Briumvi (ublituximab) for relapsing multiple sclerosis (MS).

Vaccines 98

Vaccines Chemotherapy Generic Medicine 98